Hi,Regarding last year's presentation, comercialisation of dermacan will start early in 2022 in the United States and South Africa.What does the board think, will this (combined with reducing the cash burn) move AusCann to a positive cash flow?My hope is still CPAT1 but this will still take years.
Cheers
Nauscher
- Forums
- ASX - By Stock
- Ann: December 2021 Quarterly Activities and Cashflow Reports
Hi, Regarding last year's presentation, comercialisation of...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)